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Background: Optimization of the clinical care process by integration of evidence-based knowledge is one of the
active components in care pathways. When studying the impact of a care pathway by using a cluster-randomized
design, standardization of the care pathway intervention is crucial. This methodology paper describes the
development of the clinical content of an evidence-based care pathway for in-hospital management of chronic
obstructive pulmonary disease (COPD) exacerbation in the context of a cluster-randomized controlled trial (cRCT)
on care pathway effectiveness.
Methods: The clinical content of a care pathway for COPD exacerbation was developed based on recognized
process design and guideline development methods. Subsequently, based on the COPD case study, a generalized
eight-step method was designed to support the development of the clinical content of an evidence-based care
pathway.
Results: A set of 38 evidence-based key interventions and a set of 24 process and 15 outcome indicators were
developed in eight different steps. Nine Belgian multidisciplinary teams piloted both the set of key interventions
and indicators. The key intervention set was judged by the teams as being valid and clinically applicable.
In addition, the pilot study showed that the indicators were feasible for the involved clinicians and patients.
Conclusions: The set of 38 key interventions and the set of process and outcome indicators were found to be
appropriate for the development and standardization of the clinical content of the COPD care pathway in the
context of a cRCT on pathway effectiveness. The developed eight-step method may facilitate multidisciplinary
teams caring for other patient populations in designing the clinical content of their future care pathways.
Keywords: Critical pathway, Evidence based medicine, Standardization, Cluster randomized trial, Chronic
obstructive pulmonary diseaseBackground
Standardization of the clinical care process through inte-
gration of evidence-based knowledge has proven to be
an effective strategy for reducing unwanted variations in
treatment and for minimizing the probability of medical
errors [1]. However, major difficulties arise when intro-
ducing evidence and clinical guidelines into routine daily* Correspondence: cathy.lodewijckx@med.kuleuven.be
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distribution, and reproduction in any mediumpractice, and many patients, as a result, do not receive
appropriate care, or receive unnecessary or harmful care
[2-5].
A possible tool to facilitate implementation of evi-
dence into practice is a care pathway. Care pathways are
complex interventions for mutual decision making,
organization, and standardization of predicTable care for
a well-defined group of patients during a well-defined
period [6-8]. One of the active ingredients in care path-
ways is the integration of a set of evidence-based key
interventions [8,9].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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organization (that is, patient, team, hospital); conse-
quently, variability at individual level outcomes may re-
flect the impact of higher-level complexity processes.
To deal with these multilevel effects, cluster rando-
mized designs are strongly recommended when study-
ing the impact of care pathways [10,11]. Importantly, in
cluster randomized controlled trials (cRCTs) the care
pathway under evaluation is implemented at different
sites. Consequently, a challenge within cRCT designs is
to standardize the intervention in order to deliver the
‘same’ intervention at the different sites under study
[10,12-14]. Standardization in complex interventions
refers to adaptation of the care pathway components to
the context level, without compromising the integrity of
the intervention being evaluated across multiple sites
[10,14,15].
In 2009, the European Pathway Association (E-P-A)
launched the European Quality of Care Pathways
(EQCP) study, an international cRCT addressing the im-
pact of a care pathway for chronic obstructive pulmon-
ary disease (COPD) exacerbations [9]. In the context of
the EQCP study, the clinical content of a model COPD
care pathway - implementable at the different experi-
mental sites - needed to be developed, including a set of
clinically applicable evidence-based key interventions
and a set of reliable process and outcome indicators.
This paper describes the development of the clinical
content of a care pathway for in-hospital management of
COPD exacerbation.Methods
The clinical content of an evidence-based care pathway
for COPD exacerbation was developed based on the
process design methodology developed by Berry et al.
[16], and the guideline development methods of the
American College of Chest Physicians (ACCP) [17], the
World Health Organization (WHO) [18] and the Health-
care Infection Control Practices Advisory Committee
(HICPAC) [19]. Subsequently, based on the experiences
of the COPD case, a generalized eight-step method for
development of the clinical content of an evidence based
care pathway was designed (Figure 1). This study was
approved by the ethical committee of the University Hos-
pitals Leuven as previously published in this journal [9].Results
A set of 38 evidence-based key interventions and a set of
24 process and 15 outcome indicators were developed in
eight different steps. Both sets are displayed in Additional
file 1 and Additional file 2, respectively. In the following
section, description and rationale for each development
step is presented.Step 1: Selection of the care population and selection of
an expert panel
The patient population under study was specified as
‘Patients hospitalized with COPD exacerbation’. To en-
sure clinical validity and feasibility of the end product, an
expert panel was involved in each step of the develop-
ment method. This panel was composed of the following:
(i) three clinicians with internationally recognized clinical
and scientific expertise in COPD exacerbations: a re-
spiratory physician (MD) who is also president of the
European Respiratory Society, a physiotherapist (TT)
who specializes in pulmonary rehabilitation, and a clin-
ical nurse specialist in COPD (CL); (ii) an epidemiologist
(MP) who specializes in organization of primary and sec-
ondary chronic care; and (iii) two professors (WS, KV) in
patient care management who have extensive clinical and
scientific expertise in development and implementation
of care pathways [8,18-21]. All six experts had extensive
research experience.
Step 2: Literature review and extraction of clinical
activities
To identify all available evidence for integration in the
evidence-based COPD care pathway, an extensive litera-
ture review was conducted by the main researchers, CL
and KV (Figure 2). First, an initial literature search was
carried out in April 2008 in the context of the Delphi
study, and an updated search was performed in June
2011. In the following section, the updated search is
described [22].
The following resources were explored: (I) websites
of international respiratory societies: American Thoracic
Society (ATS) (www.thoracic.org); British Thoracic Society
(BTS) (www.brit-thoracic.org.uk); European Respiratory
Society (ERS) (www.ersnet.org); Global Strategy for Diag-
nosis, Management, and Prevention of COPD (GOLD)
(www.goldcopd.org); National Institute for Health and
Clinical Excellence (NICE) (www.nice.org.uk); Scottish
Intercollegiate Guidelines Network (SIGN) (www.sign.ac.
uk); (II) Public resources for evidence-based clinical prac-
tice guidelines (www. guideline.gov, www.g-i-n.net); (III)
electronic databases including Medline and Embase and
Cochrane; (IV) available process flow diagrams founded
on evidence-based medicine (www.mapofmedicine.com,
http://group.bmj.com/products/evidence-centre.com).
For guidelines developed by international societies,
only those guidelines were considered that were updated
within the last five years. For PubMed and Cochrane, we
used the MeSH terms ‘COPD’ combined with (i) ‘prac-
tice guideline’, (ii) ‘disease exacerbation and patient care
management’, and (iii) ‘outcomes’. For Embase, we used
the MeSH terms ‘chronic obstructive lung disease’ com-
bined with (i) ‘practice guideline’ and (ii) ‘disease exacer-
bation and patient care’, and (iii) ‘outcomes’. Non-MeSH
2. Literature review & identification of 
clinical activities and outcomes
3. International Delphi study: Rating of 
content validity
4. Final selection of clincal activities & 
grading of evidence
5. Process flow chart: Categorisation of 
clinical activities into key interventions 
+ subcomponents
• Selected literature: guidelines (n=3); care maps 
(n=2); reviews (n=3)
• Identified clinical activities: n=58
• Identified outcomes: n=34
• Process indicators with content validity > 75%: 
n=21/72 (36.1%)
• Outcome indicators with content validity > 75%: 
n=10/21 (47.6%)
• Additonal clinical activities suggested by experts: 
n=19
• Final selected clinical activities: n=77
• Grading: A: 39.0%; B: 50.6%; C: 1,3%; D: 6,5% †
• 77 clinical activities => 38 key interventions + 
subcomponents
• Process flow chart: 3 core processes
• Piloting by nine in-hospital multidisciplinary COPD
teams
1. Specification of the care population & 
composition of an expert panel
• Population: patients hospitalised with COPD 
exacerbation
• Panel: Respiratory physician, physiotherapist, 
clinical nurse specialist, epidemiologist, two experts 
in patient care management
8. Piloting by multidisciplinary teams in 
different organisations
• Set of indicators: n=24 process and 15 outcome 
indicators
• Baseline measures: n=23 baseline variables
6. Detailed description of each key 
intervention: rationale, description, 
references and grading
• Manual with process flow chart and 38 detailed 
key interventions
7. Translation into a set of process and 
outcome indicators
Figure 1 Eight-step method for development of the clinical content of an evidence based care pathway: the case for COPD
exacerbation.
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‘exacerbation and management’. Search limit parameters
included: (i) published between 2005 and 2011, and (ii)
written in English, French, German, Italian or Dutch.
Second, we performed a two-phase screening evaluation
of publications selected from websites of the respiratory
societies, Map of Medicine and the electronic databases.
In the first phase, publications were appraised for rele-
vance based on appropriateness of the title and abstract. If
relevance was unclear, or if the abstract was unavailable,
the publication was included for further appraisal of the
full text. In the second phase, two independent researchers
(CL and KV) reviewed the full text of the selected guide-
lines, reviews or process flow diagrams. The following
inclusion criteria were used: (i) reportage of clinical pro-
cesses and outcomes regarding in-hospital management
of COPD exacerbation; (ii) evidence was reported in
terms of guidelines, process flow diagrams, reviews or
overview papers; (iv) published between 2005 and 2011;(v) published in English, French, German, Italian or Dutch;
and (vi) quality of underlying evidence can be appraised
by in-text references. The literature research revealed ini-
tially three guidelines, one process flow diagram, and
2,939 digital records from the electronic medical databases
(Figure 2). After exclusion of irrelevant publications (n =
2,851), and after appraisal of full text, three guidelines, two
process flow diagrams, and 37 reviews were included for
development of the evidence-based clinical content of the
COPD care pathway [5,23-56].
Finally, the selected literature was thoroughly screened
for identification of all possible clinical activities and
outcomes related to in-hospital management of COPD
exacerbation. The detected clinical activities were
extracted and listed, and the corresponding literature
sources were recorded. In total, 58 different clinical ac-
tivities were extracted from the selected literature
(Table 1, no. 1–58). Besides these, 34 outcome categories
were identified (Table 2).
• Guidelines identified through websites of 
international respiratory societies: n=3
• Process flow diagrams identified through Map of 
Medicine (MOM) and BMJ Best Practice: n=2 
• Reviews identified through electronic database 
searching: n=2939
Medline: n=739
Embase: n=2031
Cochrane: n=169
Screening on title and abstract/short description
Full text articles independently assessed for eligibility 
by two reviewers (CL & KV): 
Guidelines: n=3
Process flow diagram: n=2
Electronic records: n=88
Full text articles excluded because not 
meeting the inclusion criteria: n=51
• No exacerbation: n=20 
• No guideline: n=7
• No or limited in-text references: n=9
• Very limited description: n=4
• Duplicates: n=11
Selected for development of the clinical content:
Guidelines: n=3
Process flow diagram: n=2
Electronic records: n=37
Records excluded because not meeting 
the inclusion criteria: n=2851
Figure 2 Literature search strategy.
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validity
Content validity was rated for 72 process and 21 outcome
indicators by conducting an international Delphi study
with a panel composed of 35 medical professionals from
15 countries. This panel consisted of 19 medical doctors,
8 nurses and 8 physiotherapists. The detailed methodology
and the results of this study were published elsewhere
[57-60].
In summary, panelists were asked to rate the relevance
for follow-up of the process and outcome indicators in
care pathways for COPD exacerbations. Consensus was
defined as agreement by at least 75% of the panel mem-
bers that an indicator is relevant for follow-up. Consensus
was reached for 26 of 72 process indicators (36.1%) and10 of 21 outcome indicators (47.6%). Highest consensus
was reached for the process indicators for oxygen therapy
(100%), pulmonary rehabilitation (100%), and patient edu-
cation (94.5 to 88.6%), and for the outcome indicators for
understanding of therapy (91.4 to 85.7%) and self-
management (88.6 to 88.2%) [60].
Step 4: Final selection of the clinical activities and
grading of evidence
First, the list of 58 extracted clinical activities (step 2),
together with the Delphi results (step 3), were sent to
the clinical experts of the panel (MD, TT and CL) with a
request to complete two tasks: (i) to review the 58 iden-
tified activities for validity and feasibility; and (ii) if indi-
cated, to propose any additional clinical activity they
Table 1 Clinical activities for management of patients hospitalized with COPD exacerbation
1. Medical history before exacerbation: prior measures of lung function (B)* 37. Smoking cessation advice when active smoker (A)
2. Medical history before exacerbation: spirometric classification of severity (B) 38. Appropriate prescription of short-acting bronchodilatators (A)
3. Medical history before exacerbation: documenting frequency and
severity of attacks of breathlessness (B)
39. Appropriate prescription of long-acting bronchodilatators
(β-agonists and/or anticholinergics) (A)
4. Medical history before exacerbation: documenting frequency and
severity of chronic cough (B)
40. Appropriate prescription of inhaled corticosteroids (A)
5. Medical history before exacerbation: history of chronic
sputum production (B)
41. Appropriate prescription of glucocorticosteroids: oral
or intravenous (A)
6. Medical history before exacerbation: documenting possible limitation
of daily activities (B)
42. Appropriate prescription of methylxanthines (theophylline
or aminophylline) (A)
7. Medical history before exacerbation: prior arterial blood gas
measurements in sTable condition (B)
43. Antibiotics in patients if indicated (A)
44. Patient education information about recognition and
treatment of exacerbation (A)
8. Medical history before exacerbation: number of previous
exacerbations in the previous year (B)
45. Patient education: instruction on how to use inhalers (A)
9. Medical history before exacerbation: number of previous
hospitalizations (B)
46. Chest physiotherapy: sputum clearance (A)
47. Referral to pulmonary rehabilitation (A)
10. Medical history before exacerbation: pre-existing co-morbidities (A) 48. Monitoring of fluid balance (A)
49. Fluid administration in dehydrated patients (A)
11. Medical history before exacerbation: present treatment regimen (A) 50. Supplementary nutrition in patients with BMI <20 (B)
51. Screening and update of vaccination status (B)
12. Medical history before exacerbation: smoking status (B) 52. Deep venous thrombosis prophylaxis (A)
13. Medical history before exacerbation: sleeping and eating difficulties (B) 53. Treatment of co-morbid conditions (A)
14. Assessment of symptoms: physical examination (B) 54. Initiation of long-term oxygen therapy (LTOT) if the
patient remains hypoxemic (A)
15. Assessment of differential diagnosis (B) 55. Assessment of medical discharge criteria (D)
16. Assessment of co-morbidities (B) 56. Assessment and management of home situation (A)
17. Temperature (B) 57. Oral information and discharge letter regarding prescribed
home therapy and follow-up appointment (B)
18. Pulse rate (B) 58. Arrangement of follow-up appointment four to six weeks
after discharge (D)
19. Blood pressure (B) 59. Medical history before exacerbation: number of previous
admissions to ICU (D)
20. Alertness (B) 60. Medical history before exacerbation: cardiovascular status (B)
21. Skin color (B) 61. Glucose monitoring (B)
22. Pulse oximetry (D) 62. CT THORAX: 1 X year (B)
23. Arterial blood gas measurement: At admission (B) 63. ECHO CARDIO: 1 X year (B)
24. Arterial blood gas measurement: prior to discharge in
patients hypoxemic during a COPD exacerbation (B)
64. Patient education: information about the nature of COPD (A)
25. Arterial blood gas measurement: in the following three
months in patients hypoxemic during a COPD exacerbation (D)
65. Patient education: self-management plan (A)
26. Arterial blood gas measurement: after discharge in patients
with long term oxygen therapy (LTOT) (B)
66. Patient education strategies for minimizing dyspnoea (A)
27. Chest X-ray (B) 67. Patient education information about oxygen treatment (A)
28. ECG (B) 68. Physiotherapy: breathing techniques (A)
29. Blood examination: hematology (B) 69. Physiotherapy: Activities of Daily Life (A)
30. Blood examination: biochemical tests (B) 70. Physiotherapy: positioning (A)
31. Blood examination: theophylline level in patients on theophylline
therapy at admission (B)
71. Identification for pulmonary rehabilitation determinant (B)
32. Sputum culture and anti-biogram (B) 72. Body mass index (BMI) determinant (A)
33. Spirometry during hospitalization (not earlier than Day 3 because
of acute condition) (C)
73. Screening for weight loss (A)
34. Admission to ICU if exacerbation is life threatening (B) 74. Referral to dietician in patient with obesity or cachexie (B)
75. Assessment and management of anxiety and depression (B)
35. Controlled oxygen therapy in hypoxemic patients (A) 76. Information letter for general practitioner (B)
36. Assisted ventilation if necessary (A) 77. Discharge checklist (B)
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exacerbations and which is lacking in the current activity
list of clinical activities. Second, a consensus meeting
was held with the entire expert panel in order to make a
final selection of the clinical activities. As a result, all 58
clinical activities were appraised to be valid and feasible.
In addition, 19 clinical activities beyond the 58 original
ones were included (Table 1, nos. 59–77). Interestingly,
for almost all these additional clinical activities, a moreor less comprehensive description was available in the
guidelines for management of stable COPD [27,32,61].
Finally, the strength of the evidence for the final 77
clinical activities was graded, so that clinicians know
how much confidence they can place on the clinical
recommendations included in the clinical care pathway
[62]. The grading was performed by the clinical nurse
specialist (CL) using the SIGN approach [63]. The grad-
ing approach of SIGN was chosen because this grading
Table 2 Identified outcomes for in-hospital management of COPD exacerbation
• Readmission: 30-day, 3-month, 6-month, 1-year • Inhaled β-agonist therapy is required no more frequently
than every four hours• Number of hospital admissions
• Interval before next admission • Patient, if previously ambulatory, is able to cope with basic needs
in his/her situation, in usual environment• Frequency and severity of exacerbation
• Mortality: in-hospital, 30-day, 3-month, 6-month, 1-year • Patient is able to eat and sleep without frequent awakening by dyspnoea
• Survival: 1-year
• Length of stay (LOS) • Patient has been clinically sTable for 12 to 24 hours
• Level of understanding of inhaler therapy • Last measure of arterial blood gases (ABGs) were accepTable
according to condition of the patient• Compliance with home oxygen therapy
• Performance of physical exercise • Patient and/or home caregiver fully understands correct use of therapy:
oral medication therapy, inhaler therapy, oxygen therapy if home
oxygen therapy
• Smoking status: 30-day, 3-month, 6-month, 1-year
• Symptoms of anxiety and depression
Patient, family, and physician are confident that the patient can
manage successfully
• Health-related quality of life (HRQL): symptoms, disability,
morbidity and quality of life; psychological well-being)
• Lung function parameters: forced expiratory volume in one
second (FEV1), forced vital capacity (FVC), inspiratory capacity
• Health status
• Quality-adjusted life expectancy measure (QALY) and
disability adjusted life years (DALY)
• Quality of sleep
• Functional capacity • Nutritional status
• Exercise capacity • Patients’ perception of coordination between hospital and
home healthcare• Physical performance: 6-minute walking distance (6-MWD),
20-MWD, shuttle walk test, maximum workload, treadmill time,
maximum oxygen uptake, quadriceps strength, hand grip force,
maximal inspiratory mouth pressure
• Patient satisfaction with therapy and care
• Adverse event related to regular clinical examination by an investigator
• Severity of breathlessness: dyspnea, symptoms at rest and
during exercise
• Cost of illness (COI) analysis
• Absenteeism
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grading of evidence [62-64]. Importantly, if the level of
evidence could not be derived based on the literature
selected in step 2, an additional literature search was
performed in Medline, Embase and Cochrane. Search
terms included ‘COPD’ and key words related to the par-
ticular key intervention. Primarily, the search for add-
itional evidence was focused on reviews performed
according to standard criteria for reviews [22]. If not
available, an additional search for clinical trials was con-
ducted. Subsequently, two other clinical experts of the
panel (MD and TT) checked the final grading. As a re-
sult, 30 activities were graded as evidence for level A
(39.0%), 41 activities as level B (53.2%), 1 activity as level
C (1.3%), and 5 as level D (6.5%) (Table 1).
An extensive list of care activities was generated by
following the above-mentioned steps. However, providing
such an exhaustive list of 77 care activities to the multidis-
ciplinary teams would likely not encourage them to use
this evidence in practice. Therefore, the next two steps were
specifically undertaken to distil the list of care activities to a
set of key interventions that would be useable and manage-
able in clinical practice.
Step 5: Clustering of clinical activities into key
interventions and categorization into process flow
diagram
First, the 77 clinical activities were clustered into key
interventions with subcomponents, based on the follow-
ing criteria: (i) clinical activities are inextricably linked to
each other (that is, measurement of basal metabolicindex, advice on malnutrition, supplementary nutrition
and so on were clustered into ‘nutrition’); (ii) clinical ac-
tivities need to be performed by a specific team member
(that is, breathing exercises, positioning and so on were
categorized under physiotherapy); (iii) clinical activities
need to be performed at a specific time point or within a
specific time span of the care process (that is, activities
regarding discharge management). As a result, the 77
clinical activities were clustered into 38 key interventions,
with 9 of them comprising 2 to 15 subcomponents.
Second, the key interventions were categorized into
three core processes (diagnostic, pharmacological and
non-pharmacological management), and subsequently
presented by means of a process flow diagram. In
addition, within each of three core processes, key inter-
ventions were grouped into care blocks based on the
overall content of these key interventions (for example,
education, ventilation). The process flow diagram with
the 38 key interventions is displayed in Additional file 1.
Step 6: Detailed description of the key interventions
For each key intervention, the following components
were included in the detailed description: (i) rationale,
which addresses why it is of crucial importance that the
key intervention is performed, and which describes
expected impact on patient outcomes; (ii) description,
which defines the exact content of the key intervention;
(iii) in-text references and reference list; and (iv) grading
of evidence. An example of a detailed description of a
key intervention on arterial blood gas measurements is
provided in Figure 3. In order to search for detailed
Arterial blood gas measurement
Argumentation
Measurement of arterial blood gases (ABGs) is essential to detect hypercapnia and to assess the 
severity of an exacerbation. Consequently, ABG values are the key determinant for initiating 
supplemental oxygen therapy, prescribing assisted ventilation, and prescribing home oxygen therapy. 
A PaO2 < 8.0 kPa (60 mm Hg) and/or SaO2 < 90% with or without PaCO2 > 6.7 kPa (50 mmHg) when 
breathing room air indicate respiratory failure. In addition, moderate-to-severe acidosis (pH < 7.36) 
plus hypercapnia (PaCO2 > 6-8 kPa; 45-60 mmHg) in a patient with respiratory failure is an indication 
for mechanical ventilation (Barbera et al., 1997; Calverley, 2000; Celli et al., 2004; Gibson et al., 2008; 
GOLD, 2009; NICE, 2004; Rodriguez-Roisin, 2006; Siafkas & Wedzicha, 2006).
In the Delphi study 82.9% of experts were convinced that the key intervention has a high impact on 
clinical outcomes and therefore should be included in the pathway.
Description: (Celli et al., 2004; Gibson et al., 2008; GOLD, 2009; NICE, 2004; Rodriguez-Roisin, 2006; 
Siafkas & Wedzicha, 2006)
Measurement of PaO2, PaCO2, H2CO3-, SaO2, and pH by arterial puncture (a. radialis, brachialis, or 
femoralis) while breathing room air at admission. If measurement of ABGs while breathing room air is 
not feasible (severe cases), oxygen flow (l/min) should be noted. Twenty to 30 minutes should pass 
before rechecking the gas tensions when the FiO2 has been changed.
References: 
Barbera, J. A., Roca, J., Ferrer, A., Felez, M.A., Diaz, O., Roger, N., Rodriguez-Roisin, R. (1997). 
Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary 
disease. European Respiratory Journal, 10, 1285-91.
Calverley, P.M. (2000). Oxygen-induced hypercapnia revisited. Lancet, 356:1538-1539.
Celli, B. R. & Macnee, W. (2004). Standards for the diagnosis and treatment of patients with COPD: a 
summary of the ATS/ERS position paper. European Respiratory Journal, 23(6), 932-946.
Gibson G & Macnee W. (2008). Chronic Obstructive pulmonary disease: Investigations and 
assessment of severity. In: Siafkas (Ed), European Respiratory Monograph: Management of 
exacerbation of chronic obstructive pulmonary disease (pp. 24-40). Sheffield: European Respiratory 
Society Ltd.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2009). Global strategy for the diagnosis, 
management, and prevention of chronic obstructive pulmonary disease. Last accessed: January 27, 
2010. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003
National Institute for Clinical Excellence (NICE) (2004). Chronic obstructive pulmonary disease: national 
clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and 
secondary care. Thorax, 59 (Suppl. 1), 1-53.
Rodriguez-Roisin, R. (2006). COPD exacerbations: management. Thorax 61, 535-544.
Siafkas N. M. & Wedzicha J. A. (2006). Management of exacerbation of COPD. In: Siafkas (Ed), 
European Respiratory Monograph: Management of exacerbation of chronic obstructive pulmonary 
disease (pp. 387-400). Sheffield: European Respiratory Society Ltd.
Figure 3 Example of detailed description of a key intervention: arterial blood gas measurement.
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selected publications and their reference list were
explored. Second, information from the additional litera-
ture search, performed to establish level of evidence
(step 4), was included.
Step 7: Translation into a set of process and outcome
indicators
Besides the set of key interventions, a set of process and
outcome indicators needed to be developed to verify
compliance to key interventions and to follow up the
impact on outcomes. First, to select the final set of indi-
cators, the expert panel convened for a consensus meet-
ing. The selection process was based on the (updated)
literature search (step 2), the Delphi survey (step 3), and
the developed set of 38 evidence-based key interventions
(step 5) [60]. As a result, a set of 24 process and 15outcome indicators was developed, which are displayed
in Additional file 2. The 24 process indicators include
measurements on performance of diagnostic, pharmaco-
logical and non-pharmacological interventions. The 15
outcome indicators include measurements on readmis-
sion, mortality, length of stay (LOS), understanding of
inhaler therapy, compliance with home oxygen therapy,
performance of physical exercise, smoking status, anxiety
and depression, health-related quality of life, manage-
ment at home, functional status, self-reported health
condition, medical consumption and an economic evalu-
ation. On the basis of their expertise, the panel also
selected a set of 15 baseline variables, including medical,
socioeconomic, demographic and COPD-specific data.
Subsequently, the selected indicators and baseline vari-
ables were operationalized into objective measurements
[65]. Based on the guidance of the Agency for Health
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gov) and the Joint Commission (www.jointcommission.
org), each indicator and baseline variable was defined in
an indicator protocol by the main researcher (CL). This
process included defining of description, rationale or re-
lation to quality, type of indicator (process, outcome,
baseline), nominator and denominator, data collection
method, data elements, data reporting (that is, propor-
tion, relative proportion), criteria to meet expected out-
comes, and references. An example of an indicator
description is detailed in Additional file 3. Subsequently,
the indicator protocol was mailed to the entire expert
panel with a request to appraise each indicator descrip-
tion thoroughly for accuracy and feasibility. A meeting
with the entire expert panel was convened to discuss the
feedback and finalize the indicator protocol.
Step 8: Piloting by multidisciplinary teams
The set of 38 key interventions, and the set of 24
process and 15 outcome indicators, were piloted by nine
Belgian experimental COPD teams in the context of the
EQCP study [9]. The multidisciplinary teams included
pulmonologists, nurses, physiotherapists, dieticians, social
workers and occupational therapists. The piloting oc-
curred in four phases. First, feasibility of data collection
was evaluated during a clinical audit before pathway im-
plementation. For this phase, 105 patients from 9 Belgium
hospitals were included [9]. Mean age was 67 years (SD:
10.0), and 68.6% of the patients were male. Approxi-
mately half of the patients had severe COPD, 21% had
moderate COPD and another 21.9% had very severe
COPD. Overall, after data analyses we determined that
data collection is feasible, and only minor adaptations
with regard to the patient record analysis were included.
Second, during a workshop in which team members of
all nine multidisciplinary COPD teams attended, the
process flow diagram, including the 38 key interventions,
was presented. Subsequently, all key interventions were ex-
tensively discussed. Third, the detailed set of key interven-
tions was provided to the study coordinator of each
hospital. We requested all members of the multidisciplinary
COPD team to extensively review the key intervention set
and subsequently to provide feedback within two weeks. As
a result, the feedback given during the workshop and pro-
vided after extensive appraisal by all teams showed that
teams were very enthusiastic about the process flow dia-
gram and underlying key interventions. Moreover, they
agreed by consensus that the set of key interventions was
valid and applicable for use in their practice.
However, the teams provided four main remarks
regarding: (i) usefulness of spirometry during exacerba-
tion because results may be inaccurate due to the com-
promised condition; (ii) feasibility of referral to
pulmonary rehabilitation with regard to condition of thepatient and availability of a rehabilitation center; (iii)
type of inhaler medications and device (nebulizer vs in-
haler); and (iv) finally content, workload and feasibility
of patient education. First, with regard to spirometry, no
hard evidence about accuracy and, thus, usefulness of
spirometric tests during exacerbation is available and,
thus, no specific guidance on whether or not to perform
spirometric tests could be provided to the teams. This
issue was specifically emphasized in the detailed set of
key interventions. Concerning pulmonary rehabilitation,
all teams were convinced about the importance of refer-
ring patients to rehabilitation, and consequently, during
the workshop some alternatives with regard to availabil-
ity of a rehabilitation center were discussed. Finally, with
regard to inhaler therapy and patient education, a teach-
ing workshop was organized and education tools for
COPD teams and ready-to-use patient leaflets were
provided.
Finally, the nine multidisciplinary COPD teams imple-
mented the set of key interventions as an active compo-
nent of their care pathway for in-hospital management of
COPD exacerbation in the context of the EQCP study [9].
Six months after the start of development and implemen-
tation of the care pathway, the nine teams had the oppor-
tunity to report experiences, barriers and successful
actions during a workshop. One major difficulty in imple-
menting the educational package into the daily
work routine was reported. Overall, the teams confirmed
validity and clinical applicability of the set of 38 key
interventions.
Discussion
A set of 38 evidence-based key interventions for in-
hospital management of COPD exacerbation was devel-
oped (see Additional file 1) and, subsequently, piloted and
validated by multidisciplinary COPD teams from nine dif-
ferent hospitals. This overall approval indicates that the
applied strategy is appropriate for the development and
standardization of the clinical content of an evidence-
based care pathway. Second, a set of 24 process and 15 out-
come indicators was also developed (see Additional file 2).
The pilot study showed that the measurements on the
indicators were feasible for the multidisciplinary teams
and the patients; only some minor adaptations were
required. Subsequently, based on our experience and what
we have learned from the COPD case, we designed a gen-
eralized eight-step method (Figure 1), with the aim to
guide and inspire teams caring for other patient groups in
designing the clinical content of their future evidence-
based care pathways.
It is important to note that designing the care pathway
content according to the eight-step strategy is a time-
consuming process, especially with regard to the Delphi
survey (step 3) and pilot testing (step 8). However,
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ensure that the key intervention set is widely, clinically
applicable. This is especially important when conducting
a cRCT, in which the ‘same’ care pathway intervention
needs to be implemented by different teams at different
sites and possibly in different countries [9]. Teams devel-
oping care pathways should carefully plan an implemen-
tation strategy and budget enough time in their project
plan for proper development of the clinical content of
their care pathway.
A surprising finding is that, based on review of the litera-
ture (Step 2), the Delphi study, and face-to-face expert
opinion, advanced care planning was not included in the
set of 38 key interventions. On one hand, this can be
explained due to the focus on management of acute COPD
exacerbation. On the other hand, it is essential that
advanced care planning and end of life discussions are
initiated in advance of a life threatening situation, which
can arise after COPD exacerbation [66]. Therefore, we ac-
knowledge that an additional key-intervention with detailed
reference to and description of advance life care planning
should be included in this key intervention set.
An important limitation in the current strategy is the lack
of patient involvement [67]. Patients can bring a different
perspective to the quality improvement process, as they are
likely to prioritize different aspects of care compared to
clinicians, including interpersonal and amenity aspects; for
example, communication with healthcare staff and quality
of the food, rather than the technical and clinical aspects
[68]. We believe that patients, for instance, by contacting
patient societies, should have been involved in three phases
of the eight-step method: (i) step 4: Final selection of the
clinical activities; (ii) step 7: Translation into a set of indica-
tors; and (ii) step 8: Piloting of the final set of key interven-
tions. Including patients in these phases could have
provided extra activities and outcomes, important from the
patient perspective. After implementation of the key inter-
ventions, it will be interesting to gather information on pa-
tient preferences and opinions by performing open
interviews with the patient and relatives, or by performing
walk-throughs together with the patient [69]. Also, when
applying the evidence-based care intervention in daily prac-
tice, clinicians should ensure that each of their individual
patients is involved in decision making [67]. In this context,
it is also recommended to develop a patient version that
includes a brief and understandable summary of the set of
key interventions.
We believe that developing the clinical care pathway
content by using this newly developed and validated
eight-step method will facilitate adequate integration of
evidence-based knowledge into daily practice. Since the
beginning of the 1990s, evidence-based clinical practice
guidelines for almost all domains of medicine have been
available worldwide, accessible more recently via theInternet [4,70,71]. However, we see high variability in the
integration of knowledge from evidence-based guidelines
into daily practice [4,72]. Common barriers for integra-
tion of evidence-based knowledge are disagreement with
the evidence; lack of outcome expectancy; lack of time;
and available evidence, such as guidelines being unneces-
sarily complex, and thus not so directly applicable for
clinical practice [4,72,73]. This eight-step methodology
can facilitate translation of evidence-based knowledge
into clinically applicable key interventions, which can
overcome barriers and assist clinicians both in selecting
the best treatment options and in delivering safe and ef-
fective care [4]. However, besides providing a set of
detailed evidence-based key interventions, consideration
of factors like culture (safety, commitment to do better
in practice, peer norms); teamwork; skills management;
communication; leadership alignment; and support will
be critical to successfully integrate evidence into practice
and improve the care process [74]. In this context, care
pathways can be very effective tools, as they bring all
these pieces together [8,25,75].
Finally, we want to emphasize the potential role of pro-
fessional medical associations in clinical content develop-
ment for evidence-based care pathways. Many national
and international societies have extensive clinical and
research experience in the patient population of their
clinical field, comprise a global network of experts in
the field, have funding available and, last but not least,
have comprehensive understanding and experience in
synthesizing evidence-based knowledge and making
this knowledge usable for daily clinical practice. There-
fore, we believe that professional societies could play a
major role in developing the clinical content of future
evidence-based care pathways, especially in terms of clin-
ical support, expert networking and input of resources.
Conclusion
The set of 38 key interventions and the set of process
and outcome indicators were found to be appropriate
for the development and standardization of the clinical
content of the COPD care pathway in the context of a
cRCT on pathway effectiveness. The developed eight-
step method may facilitate multidisciplinary teams car-
ing for other patient populations in designing the clinical
content of their future care pathways.Additional files
Additional file 1: Process flow diagram for in-hospital management
of COPD exacerbation. This Additional file displays a process flow chart
including 38 key interventions that should be performed for every
patient entering the hospital with COPD exacerbation. The key
interventions are classified under three core processes: Diagnostic,
Pharmacological and Non-pharmacological management.
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http://www.trialsjournal.com/content/13/1/229Additional file 2: Set of Process and outcome
indicators for in-hospital management of COPD exacerbation. This
Additional file displays a set of validated process and outcome indicators
for audit of care for in-hospital management of COPD exacerbation.
Additional file 3: Example of description of an indicator. This
Additional file displays the detailed description of an indicator according
to the guidance of the Agency for Health Care Research and Quality
(www.qualitymeasures.ahrq.gov) and the Joint Commission (www.
jointcommission.org).
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